Liang is an Associate of Cure Ventures. He has over 10 years of research experience in cancer genetics and therapeutics. Prior to joining Cure, he completed his PhD research work from Bill Sellers Lab at the Broad Institute of MIT and Harvard. His work provides the first systematic characterization of pathway activation as a new class of cancer dependency, laid the scientific groundwork for a new biotech company. He also identified the misapplication of therapeutic development paradigm in previous efforts to target pan-essential genes in oncology. He published first-authored publications in high-impact journals including Nature Genetics and Cancer Cell.
In addition to his academic research, Liang has over 2 years of experience in life science venture capital, venture creation, and university technology commercialization. He was a Fellow at 5AM Ventures where he helped with biotech venture investment and new company building, a Venture Fellow at Flagship Pioneering where he engaged in conceiving and developing new biotech company concepts, and a Senior Business Development Fellow at Harvard Office of Technology Development where he contributed to the commercialization effort of the Harvard life science technology portfolio.
Liang received his Ph.D. in Biological and Biomedical Sciences from Harvard University, and his B.A. in Biology with Honors at Macalester College.